🇺🇸 NKTR-214 in United States

54 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 54

Most-reported reactions

1. Acute Kidney Injury — 9 reports (16.67%)
2. Malignant Neoplasm Progression — 9 reports (16.67%)
3. Hypotension — 6 reports (11.11%)
4. Atrial Fibrillation — 5 reports (9.26%)
5. Cerebrovascular Accident — 5 reports (9.26%)
6. Dehydration — 5 reports (9.26%)
7. Pyrexia — 5 reports (9.26%)
8. Respiratory Failure — 4 reports (7.41%)
9. Death — 3 reports (5.56%)
10. Hyponatraemia — 3 reports (5.56%)

Source database →

Frequently asked questions

Is NKTR-214 approved in United States?

NKTR-214 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NKTR-214 in United States?

Bristol-Myers Squibb is the originator. The local marketing authorisation holder may differ — check the official source linked above.